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Human pluripotent stem cells possess the potential to generate cells for regenerative
therapies in patients with neurodegenerative diseases, and constitute an excellent cell
source for studying human neural development and disease modeling. Protocols for
neural differentiation of human pluripotent stem cells have undergone significant progress
during recent years, allowing for rapid and synchronized neural conversion. Differentiation
procedures can further be combined with accurate and efficient positional patterning
to yield regionalized neural progenitors and subtype-specific neurons corresponding to
different parts of the developing human brain. Here, we present a step-by-step protocol
for neuralization and regionalization of human pluripotent cells for transplantation studies
or in vitro analysis.
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INTRODUCTION
Given that the human brain is far more complex than brains of
rodents, chicks, or invertebrate model organisms, it is clear that
knowledge of human brain development cannot be fully extrap-
olated only from animal models. Therefore, studies on human
fetal tissue in combination with a reliable human in vitro mod-
eling system are required. Due to very limited access to fetal tissue
at different developmental time points, human cell sources such
as pluripotent cells are necessary to allow for comprehensive,
dynamic analysis of human neural development, and to gener-
ate sufficient amounts of cells for future regenerative therapies
(Kirkeby and Parmar, 2012).
Based on previously published methods for neural differen-
tiation (Zhang et al., 2001; Perrier et al., 2004; Nat et al., 2007;
Chambers et al., 2009; Fasano et al., 2010), we have developed
and refined a standardized protocol for rapid neural conversion
of pluripotent cells using defined culture settings free of feeder
cells, matrigel, knockout serum replacement (KSR), and manual
picking steps (Kirkeby et al., 2012). By mimicking developmen-
tal cues important for neural tube patterning in mammals, the
cells can be efficiently patterned to regionalized cultures of a high
purity. The protocol presented here is based on rapid neural con-
version through dual SMAD inhibition (Chambers et al., 2009)
and regionalization of the cells in this protocol constitutes a flex-
ible system controlled by dose-dependent chemical inhibition of
glycogen synthase kinase 3 (GSK3) for rostro-caudal patterning
and dose-dependent activation of sonic hedgehog (SHH) and
bone morphogenetic protein (BMP) signaling for dorso-ventral
patterning (Kirkeby et al., 2012).
DIFFERENTIATION PROCEDURE
The protocol presented here will produce neural cells of a telen-
cephalic fate in the absence of any patterning factors. To control
rostro-caudal and dorso-ventral patterning, see separate section
below. This protocol is preferably started on a Monday to avoid
medium changes during the weekends (see overview of differ-
entiation procedure in Figure 1). It is important to start the
differentiation with healthy, pluripotent cells. All differentiated
colonies should be removed from the culture before initiating
differentiation.
Optional: If pluripotent cells are cultured on mouse embry-
onic fibroblasts (MEFs), colonies can be passaged ontomatrigel in
conditioned media or onto vitronectin in Essential 8 medium for
1 passage (3–7 days) before starting differentiation. This step will
remove MEFs from the culture. Differentiation may also be ini-
tiated from colonies on MEFs, but if too many MEFs are present
in the culture, this may result in attachment of embryoid bodies
(EBs) to the bottom of the culture dish.
1. Day 0: Check that the colonies appear pluripotent by visual
criteria, and if needed, remove differentiated colonies from the
culture. Aspirate hESC media and wash cells once in PBS. Add
minimal volume of EDTA (0.5mM) to the cells (i.e., 0.5ml for
a 6-well) and incubate at 37◦C for 5–8min until colonies are
easily washed off the dish with a pipette.
2. Gently pipette colonies off the dish and spin down in 10ml
culture medium at 200× g for 5min.
NOTE: When dissociating cells with EDTA, a washing step
is not necessary. Here, cells are spun down to avoid dilution of
the differentiation medium with EDTA solution. Alternatively,
colonies can be enzymatically dissociated with dispase, but this
requires additional washing steps and may result in a lower
cell yield.
3. To start differentiation, re-suspend the cells in differentiation
medium: NIM + Y-27632 (10μM) + SB431542 (10μM) +
noggin (100 ng/ml). The volume of differentiation medium
will depend on the amount of starting material. In general,
the volume of differentiation medium should be equivalent
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FIGURE 1 | Overview of differentiation protocol. Cells are differentiated as
EBs for the first 4 days, and then cultured as attached colonies on coated
plates with subsequent dissociation and replating at day 11. Neuralisation and
patterning factors are present between day 0–9 (only SB431542 is withdrawn
at day 7), and terminal differentiation is initiated from day 14 and onward with
db-cAMP and DAPT.
to 1–1.5× the volume of growth medium used for the
undifferentiated cells. That is, if starting with cells from 1
well of a 6-well plate, the differentiation volume should be
1.5–2.5ml depending on the density of the cells. Plate cell
suspension in non-treated cell culture plates for EB forma-
tion (i.e., 0.5ml/well in a 24-well plate or 1ml/well in a
12-well plate). Optional patterning factors can be added to
the medium as needed (see section “Rostro-caudal and Dorso-
ventral patterning of neural progenitors”).
NOTE: ROCK inhibitor is added to the differentiation
medium from day 0–2 to increase survival of EBs. If Fc-
conjugated noggin is used, add 200 ng/ml noggin instead of
100 ng/ml. For some cell lines, 10μMSB431542may appear toxic,
and the concentration should then be lowered to 2–5μM. Start
coating with poly-ornithine (PO) on this day.
4. Day 2: Transfer EB suspensions to a tube and spin down gen-
tly at 80× g for 5min. Aspirate the medium and re-suspend
the EBs in new NIM medium + SB431542 (10μM) + nog-
gin (100 ng/ml) + optional patterning factors using the same
volume as on day 0. Return EBs to the wells they came from.
NOTE: If necessary, wash wells with medium to retrieve any
EBs that have attached to the well bottom. If big aggregates of EBs
are present, these should be broken up with a pipette. If medium
is very yellow by day 2, increase the volume of differentiation
medium. Coat plates with fibronectin and laminin (FN/lam) on
this day.
5. Day 4: Transfer EB suspensions to a tube and spin down
gently at 80× g for 5min. Resuspend EBs in NPM medium
+ SB431542 (10μM) + noggin (100 ng/ml) + optional pat-
terning factors. The volume of differentiation medium should
now be 2× the previous volume. Transfer EBs to wells coated
with PO/lam/FN (see section “Reagent Setup”) corresponding
to a 1:2 split. If big aggregates of EBs are present, these should
be broken up with a pipette before plating.
6. Day 7: Replace medium with NPM medium + noggin
(100 ng/ml) + optional patterning factors. Coat with PO on
this day.
7. Day 9: Replace medium with plain NPM medium without
growth factors or patterning factors. Coat with FN/lam on
this day.
8. Day 11: Replating: Wash cells with PBS, and add minimal vol-
ume of accutase to the wells. Leave cells in the incubator for
10min or longer, until cells are easily suspended from the dish
with a pipette. Dissociate cells with a pipette and spin down
at 300× g for 5min (before spinning, take an aliquot out for
cell counting). Resuspend cells to a density of 5–15,000 cells/μl
in NDM medium. Wash freshly coated plates with PBS and
remove all liquid from the plates with a vacuum aspirator to
achieve completely dry wells. Plate cells in droplets of 5–100μl
depending on future use. If many small wells are needed for
immunocytochemistry, droplets of 5μl can be plated in indi-
vidual wells of 48-well plates to yield multiple replicates. If
large amounts of cells are needed for transplantation or sort-
ing, all cells can be plated in a single large droplet. Leave dishes
in the incubator for 15–20min to allow cells to attach to the
well bottom. When attachment is verified in the microscope,
add medium to the wells: NDM + BDNF (20 ng/ml) + GDNF
(10 ng/ml) + AA (0.2mM).
NOTE: The cell density at this point is critical for the sur-
vival and proper differentiation of the cells, and optimal density
should be adapted for each individual purpose. The cells need to
be maintained at a very high density to avoid cell death and selec-
tive loss of neural subtypes. On the other hand, if the cell density
is too high, neuronal maturation will be attenuated.
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9. Day 14: Change medium to NDM + BDNF (20 ng/ml) +
GDNF (10 ng/ml) + ascorbic acid (0.2mM) + db-cAMP
(500μM) + DAPT (1μM). Maintain the cells in this
medium from now and onward to induce terminal neuronal
maturation.
NOTE: Cells are at an optimal stage for transplantation
between days 14–20 of differentiation. If cells are to be used for
transplantation, avoid adding DAPT to the medium, as this will
result in premature neuronal maturation causing increased cell
death upon dissociation.
Optional: If cells are needed for long-term studies of mature
neuronal phenotype, it may be necessary to replate cells again
between days 16 and 20 to avoid too high density of the cultures.
In that case, perform replating using the same procedure as on day
11. Replating at later timepoints should be avoided due to stress
on mature neuronal cells. At late stages of differentiation, neu-
rons may begin to detach from the plate. This can be attenuated
by adding lam + FN to the cell culture medium.
ROSTRO-CAUDAL PATTERNING OF NEURAL PROGENITORS
Rostro-caudal patterning of the cells can be controlled by dose-
dependent addition of the GSK3 inhibitor CHIR99021/CT99021.
The compound should be added to the cells from day 0 to 9 of
differentiation at an appropriate concentration for the purpose
needed. Use 0.2–0.4μM for diencephalic fates; 0.6–0.8μM for
mesencephalic fates, 1–2μM for anterior rhomencephalic fates
and ≥4μM for posterior rhomencephalic fates. Since different
cell lines may show variations in the response to GSK3 inhibition,
we recommend that each lab performs a dose-response curve of
the CHIR99021 to determine the optimal concentration needed
for generating the wanted cell type in their settings. Read section
“Reagent Setup” for instructions on CHIR99021 preparation.
DORSO-VENTRAL PATTERNING OF NEURAL PROGENITORS
Ventralization of the cells can be obtained by adding Shh-C24II
to the medium from day 0 to 9 of differentiation at any given con-
centration of CHIR99021. If no Shh is added to the culture, the
cells will be enriched for alar plate fates. To enrich for basal plate,
add 50–150 ng/ml, and to enrich for floor plate, add ≥200 ng/ml
Shh-C24II. If more potent ventralization is wanted, purmor-
phamine (0.5μM) can be added together with Shh from day
2 to 9. To achieve dorsalization of cultures toward roof plate fates,
remove SB431542 and noggin from the cultures at day 4 to allow
for BMP activation.
NOTE: Chemical compounds are generally used at lower con-
centrations in this protocol compared to protocols using knock-
out serum replacement (KSR) in the differentiation medium
(Kriks et al., 2011). This may be due to a higher protein content
and chemical buffering capacity in media containing KSR, neces-
sitating higher concentrations of chemical patterning factors.
Higher concentrations of chemical factors in this protocol may
result in toxicity (purmorphamine shows beginning toxicity at
1μM, CHIR99021 at 8μM and DAPT at 3μM in this protocol).
Different batches of Shh-C24II may have different potencies, thus
requiring adjustments in concentration.
MATERIALS (EUROPEAN CATALOG NUMBERS)
• Human embryonic stem cells or induced pluripotent stem
cells of good quality with minimal spontaneous differentiation.
Grown onmouse embryonic feeder cells or in defined medium
on matrigel or vitronectin.
• EDTA 0.5M pH 8.0 (15575–020). Dilute to 0.5mM in PBS and
store at RT.
• DMEM/F-12 (Invitrogen, cat. no. 21331–020).
• Neurobasal (Invitrogen, cat no. 21103–049).
• L-Glutamine (200mM, Invitrogen, cat. no. 25030–081),
aliquot and store at −20◦C.
• Accutase (Invitrogen, cat. no. A11105–01), aliquot and store at
−20◦C.
• B27 supplement without vitamin A (Invitrogen, cat no 12587–
010), aliquot and store at −20◦C.
• N2 supplement (Invitrogen, cat no 17502–048), aliquot and
store at −20◦C.
• SB431542 (TGFβ inhibitor, Tocris Bioscience, cat. no. 1614 or
Axon Medchem, cat. No. 1661). Make stock aliquots of 20mM
in DMSO and store at −20◦C.
• Y-27632 dihydrochloride (ROCK inhibitor; Tocris
Bioscience, cat. no. 1254 or Axon Medchem 1683).
Make stock aliquots of 10mM in H2O and store
at −20◦C.
• CHIR99021/CT99021 (GSK3 inhibitor; Axon Medchem, cat
no 1386). Make stock aliquots of 10mM in DMSO and store
at −20◦C.
• Recombinant human Noggin (R&D Systems, cat. no.
6057-NG)∗.
• Recombinant human BDNF (R&D Systems, cat. no.
248-BD)∗.
• Recombinant human GDNF (R&D Systems, cat. no.
212-GD)∗.
• Recombinant modified human Sonic Hedgehog C24II (R&D
Systems; cat. no.1845-SH-025)∗.
• Purmorphamine (Smoothened agonist; Stemgent 04-0009).
Make stock aliquots of 10mM in DMSO and store
at −20◦C.
• Ascorbic acid (Sigma, cat. no. A5960). Make stock aliquots of
200mM in H2O and store at −20◦C.
• Dibutyryl-cAMP (Sigma cat no. D0627). Make stock aliquots
of 50mM in H2O and store at −20◦C.
• DAPT (γ-secretase inhibitor; Tocris Bioscience, cat no. 2634).
Make stock aliquots of 10mM in DMSO and store at −20◦C.
• Polyornithine (Sigma cat no. P3655). Make sterile filtered stock
aliquots of 1.5mg/ml in H2O and store at −20◦C.
• Laminin (Invitrogen cat no. 23017-015). Aliquot and store
at −80◦C.
• Fibronectin (Invitrogen cat no. cat no 33010-018). Make
stock aliquots of 0.5mg/ml in PBS + 5mM NaOH and store
at −20◦C.
• Non tissue-culture treated multiwell plastic plates (12- or
24-wells).
• Tissue-culture treated multiwell plastic plates (12-, 24-, or
48-well).
• PBS.
• Sterile water.
Frontiers in Cellular Neuroscience www.frontiersin.org January 2013 | Volume 6 | Article 64 | 3
Kirkeby et al. Protocol for region-specific neuralization of stem cells
∗For protein growth factors, make stock solutions in
PBS + 0.1% BSA and store at −20◦C.
REAGENT SETUP
Neural induction medium (NIM):
DMEM/F-12: Neurobasal (1:1)
1× N2 (1:100)
1× B27 (1:50)
2mM L-Glutamine (1:100)
Neural proliferation medium (NPM):
DMEM/F-12: Neurobasal (1:1)
0.5× N2 (1:200)
0.5× B27 (1:100)
2mM L-Glutamine (1:100)
Neural differentiation medium (NDM):
Neurobasal
1× B27 (1:50)
2mM L-Glutamine (1:100)
POLYORNITHIN/LAMININ/FIBRONECTIN (PO/lam/FN)
COATED DISHES
For coating, dilute PO stock solutions 1:100 inH2O to yield a final
concentration of 15μg/ml. Add the solution to wells and incu-
bate at 37◦C for 48 h (i.e., 0.2ml/cm2 = 350 ul in a 24-well dish
and 700 in a 12-well dish). After 48 h, aspirate the PO solution
and wash three times in sterile H2O. Prepare FN + lam solu-
tion by adding 1:100 of FN (0.5mg/ml) to PBS in a 50ml tube.
Swirl the tube well to ensure that FN is in solution (ensure that is
does not form a precipitate or sticks to the tube wall). Then place
the tube at 4◦C for 15–30min to cool down the solution. In the
meantime, thaw an aliquot of laminin at 4◦C. When the PBS-FN
solution is cold, add laminin to the tube to yield a final concen-
tration of 5μg/ml for each. Swirl the tube. Immediately add the
FN/lam solution to the washed PO-coated wells at 0.2ml/cm2 and
incubate at 37◦C for 48–72 h. Wash the plates twice in PBS prior
to plating the cells. Plates incubating with FN/lam solution can be
left in the incubator for up to 1 week before use.
DILUTION OF CHIR99021/CT99021
Since patterning with CHIR99021 is extremely concentration
dependent, it is important that the compound is diluted in exactly
the same way for every experiment. The compound should be
kept frozen and exposure to light should be minimized to avoid
degradation.
• Keep CHIR99021 stock aliquots (10mM in DMSO) at −20◦C.
• These aliquots can be thawed and used up to three times, and
in between they should be stored at −20◦C.
• For use in experiments, thaw the frozen aliquot and dilute 3μl
in 297μl medium (1:100) to yield a 100μM solution. Aim
at always using the same pipettes for dilution to avoid drifts
in concentration between experiments. Always use freshly pre-
pared dilutions for experiments.
• Mix well and add the 100μM solution to the cells to yield the
desired concentration (i.e., for 0.8μMfinal concentration, add
8μl solution to 1ml of medium).
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